Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
Janusz Mezynski, Carmel Pezaro, Diletta Bianchini, Andrea Zivi, Shahneen Sandhu, E. Thompson, John W. Hunt, Elizabeth Sheridan, Bindumalini Rao Baikady, Ajit Sarvadikar, Gal Maier, Alcuin Reid, Amy Mulick, David Olmos, Gerhardt Attard, Johann S. de Bono (2012). Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?. , 23(11), DOI: https://doi.org/10.1093/annonc/mds119.
